GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (NAS:OMCL) » Definitions » Operating Income
中文

Omnicell (Omnicell) Operating Income

: $-35 Mil (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Omnicell's Operating Income for the three months ended in Dec. 2023 was $-23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-35 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Omnicell's Operating Income for the three months ended in Dec. 2023 was $-23 Mil. Omnicell's Revenue for the three months ended in Dec. 2023 was $259 Mil. Therefore, Omnicell's Operating Margin % for the quarter that ended in Dec. 2023 was -9.03%.

Omnicell's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Omnicell's annualized ROC % for the quarter that ended in Dec. 2023 was -4.49%. Omnicell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -41.27%.


Omnicell Operating Income Historical Data

The historical data trend for Omnicell's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.35 35.53 89.51 -2.32 -34.87

Omnicell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.36 -22.96 7.75 3.71 -23.37

Omnicell Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omnicell  (NAS:OMCL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Omnicell's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-93.46 * ( 1 - 22.37% )/( (1614.945 + 1617.453)/ 2 )
=-72.552998/1616.199
=-4.49 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2221.575 - 148.172 - ( 458.458 - max(0, 369.361 - 913.751+458.458))
=1614.945

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2226.878 - 129.586 - ( 479.839 - max(0, 367.792 - 927.571+479.839))
=1617.453

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Omnicell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-93.46/( ( (132.324 + max(96.549, 0)) + (133.589 + max(90.458, 0)) )/ 2 )
=-93.46/( ( 228.873 + 224.047 )/ 2 )
=-93.46/226.46
=-41.27 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(272.584 + 116.144 + 66.565) - (148.172 + 166.507 + 44.065)
=96.549

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(252.025 + 110.099 + 85.608) - (129.586 + 175.934 + 51.754)
=90.458

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Omnicell's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-23.365/258.847
=-9.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Omnicell Operating Income Related Terms

Thank you for viewing the detailed overview of Omnicell's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Omnicell (Omnicell) Business Description

Traded in Other Exchanges
Address
2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
Executives
Kaushik Ghoshal director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Christine Marie Mellon officer: EVP, Chief People Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Randall A Lipps director, officer: President and CEO 1101 EAST MEADOW DR, PALO ALTO CA 94303
Nchacha Etta officer: EVP & CFO 4220 NORTH FREEWAY, FORT WORTH TX 76137
Joanne B Bauer director 1400 HOLCOMB BRIDGE ROAD, ROSWELL GA 30076-2199
Scott Peter Seidelmann officer: EVP, Chief Commercial Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Peter J. Kuipers officer: Executive V.P. CFO 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Manley Corey J officer: SR. VP & CHIEF LEGAL OFFICER 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Dan S Johnston officer: V.P., Legal & General Counsel
Joseph Brian Spears officer: Chief Accounting Officer & VP 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
James T Judson officer: VP Finance & Acting CFO C/O OMNICELL, INC., 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Robin Gene Seim officer: V.P., Finance & CFO 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Edward Peter Bousa director 280 CONGRESS STREET, BOSTON MA 02210
Nhat H Ngo officer: VP, Strategy & Business Dev. 490 NORTH WIGET LANE, WALNUT CREEK CA 94598